Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Tools & Techniques Drug discovery, Informatics

Old Drugs, New Computational Tools

There are about 7,000 rare or orphan diseases. But, perhaps counterintuitively, around 1 in 10 people are affected by one – so although the diseases themselves are rare, they are certainly not rare in terms of their collective impact! But as each of the individual conditions affects a small population, each represents just a small market. Unfortunately, this is what leads to these disease areas being neglected, as this small market doesn’t justify the billion-dollar drug discovery process that big pharma needs to go through to find a new drug. But of course, the human impact is huge, and the psychological and financial burden of these diseases on society, patients and their family members is immense.

The pharmaceutical industry relies on basic scientific research that is performed by universities to provide leads, and we realized that we could help find a solution to the problem. It is well known that approved drugs can bind to multiple proteins – on average they can bind to as many as six targets – which is the cause of unwanted side effects; on the other hand, it also means that one drug has the potential to affect multiple targets, and therefore to treat multiple diseases.

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!


Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Misagh Naderi

Misagh Naderi is a PhD Graduand and Computational Biochemistry Research Assistant, Department of Biological Sciences, Louisiana State University, USA.


Send me the latest from The Translational Scientist.

Sign up now

Related Articles

Research Field Cancer

Cancer and the Microbiome

| Ivan Gladwyn-Ng, Alexander Maue

Research Field Neurological

Redirecting Cell Fate

| Jonathan James

Disease Area Cancer

Two-pronged Attack on Neuroblastoma

| Jonathan James

Most Popular

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts